Generic drug freedom-to-operate isn’t about “winning” patents—it’s about designing around them.
If you’ve ever watched a generic launch get delayed by a single, stubborn patent, you already know the uncomfortable truth: the real battleground isn’t the …
Drug patents in Africa: exactly how long they last—and why that timeline matters more than most people think.
Here’s the hook: when a patent expires, it doesn’t just “open the market.” It can change the price of essential medicines, the speed of generi…
Drug Patents in Africa: Exactly How Long They Last Read Post »
ð¦ Green light to launch: the definitive step-by-step FTO analysis guide is here—and it could change how new drug products get to market.
If you’re building a new drug product (or advising one), you already know the uncomfortable truth: the science c…
Biotech investors don’t lose money because they can’t read a press release.
They lose money because they read the wrong numbers.
In a sector where a single trial update can reprice an entire company overnight, the market doesn’t really care about your …
Value a Biotech Like a Pro: The Metrics That Actually Move Price Targets Read Post »
Patent vs. Regulatory Exclusivity: The Drug Industry’s Two-Layer Protection System (Explained)
In pharma, “protection” isn’t one thing—it’s two.
And if you’re investing, building a pipeline, negotiating partnerships, or even just trying to understand w…
First-to-File, First-to-Profit: The Real Economics Behind Paragraph IV and 180-Day Exclusivity
In generic drug competition, timing isn’t just strategy—it’s value creation.
A single filing date can determine whether a company captures months of market e…
Generic and biosimilar launches don’t happen on a calendar—they happen when exclusivity breaks.
That’s the quiet truth behind formulary strategy, and it’s why payer teams are increasingly leaning on loss-of-exclusivity (LOE) data to decide when to sw…
Most people read drug pipelines after the fact. The winners read them before they’re public.
In pharma, timing isn’t just strategy—it’s advantage.
By the time a company publishes its pipeline in a glossy deck, the market has already priced in expectati…
20 Years on Paper: The Real Guide to Drug Patent Duration in the United States
Most people think drug patent life is a simple countdown: file today, expire in 20 years. In reality, the clock is messier—and the difference between “20 years” and “effecti…
20 Years on Paper: The Real Guide to Drug Patent Duration in the United States Read Post »
Pick the right patent—or leave billions on the table.
In pharma, the difference between winning and losing isn’t just the science. It’s the paperwork. The filings. The timing. And—more often than people admit—the choice of which patent you’re actuall…
Get new actionable insights and updates from BiotechBlog
